# A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

> **NCT04104321** · PHASE3 · SUSPENDED · sponsor: **Galmed Research and Development, Ltd.** · enrollment: 157 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Aramchol free acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04104321
- **Lead sponsor:** Galmed Research and Development, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-09-23
- **Primary completion:** 2022-12-08
- **Final completion:** 2027-06-30
- **Target enrollment:** 157 (ACTUAL)
- **Why stopped:** Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104321, "A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04104321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*